Abstract
To evaluate our results in terms of response, survival and toxicity profile of sunitinib among Egyptian patients with metastatic renal cell carcinoma. Between January 2010 and December 2013, 44 patients with metastatic renal cell carcinoma who received sunitinib at an oncology center of Cairo university hospitals were enrolled in this retrospective analysis. The median age of the patients was 53 years, 22 (50%) having localized disease at presentation ,while the remaining half of the patients presented with metastasis. At a median follow up of 19 months, 9 (21%) patients achieved partial remission, while disease was reported stable in 20 cases (45%) and progressive in 7 (16%), 4 (9%) being lost to follow up, and 4 (9%) had discontinued therapy due to toxicity. The median overall survival was 23 months (95%CI 15.2 - 30.9), while progression free survival was 12 months (95%CI 11.6 - 12.3). The most commonly reported non hematological grade 3 adverse events included mucositis (15.9%), hand-foot syndrome (13.6%), and fatigue (9%), while the predominant grade 3 or 4 laboratory abnormalities were neutropenia (6.8%), followed by anemia in 4.5% of patients. Our efficacy data were comparable to the published literature in terms of progr...Continue Reading
References
Sep 1, 1995·Cancer·T M LawD F Bajorin
May 1, 1998·The New England Journal of Medicine·S NegrierT Tursz
Jul 11, 2003·The Journal of Urology·Xi NaEdward M Messing
Nov 10, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I Rini, Eric J Small
Dec 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerBrian I Rini
Jun 8, 2006·JAMA : the Journal of the American Medical Association·Robert J MotzerM Dror Michaelson
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Dec 25, 2007·Lancet·Bernard EscudierUNKNOWN AVOREN Trial investigators
Dec 20, 2008·The Lancet Oncology·Ann-Lii ChengZhongzhen Guan
Mar 10, 2009·Lancet·Brian I RiniBernard Escudier
Jul 21, 2009·The Lancet Oncology·Martin E GoreRonald Bukowski
Aug 12, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nielka P van ErpHans Gelderblom
Aug 27, 2009·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Min Hee HongSun Young Rha
Nov 10, 2009·Japanese Journal of Clinical Oncology·Hirotsugu UemuraHideyuki Akaza
Feb 25, 2010·World Journal of Urology·E HerrmannC Wülfing
May 12, 2010·Japanese Journal of Clinical Oncology·Changhoon YooHanjong Ahn
May 24, 2011·BJU International·Camillo PortaEmilio Bajetta
Aug 11, 2011·Oncology·Hyo Song KimSun Young Rha
Oct 22, 2011·The Lancet Oncology·Jesus Garcia-DonasCristina Rodríguez-Antona
May 18, 2013·Asian Pacific Journal of Cancer Prevention : APJCP·Ahmet DiricanMustafa Oktay Tarhan
Sep 26, 2013·Indian Journal of Cancer·V M KrishnaH B Tangaonkar
Mar 1, 2014·Asia-Pacific Journal of Clinical Oncology·Se-Hoon LeeHyun C Chung
Mar 20, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Teruo InamotoHirotsugu Uemura